ACC 2026: pooled analysis supports early dapagliflozin use in acute HF care
On 30 March, at this year’s American College of Cardiology (ACC) Scientific Session, during a poster contributions session on the…
Cardiovascular
-
-
Theravance shuts down R&D efforts and cuts workforce by half after Phase III trial failure
Theravance Biopharma is restructuring its R&D organisation and cutting its workforce by approximately half after its rare disease blood pressure…
-
Bayer’s Factor XIa inhibitor reduces repeat stroke risk by 26% in pivotal trial
Bayer’s investigational, once-daily, oral Factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke by 26% in a pivotal…
-
JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus
At the 44th Annual JP Morgan Healthcare conference 2026, Eli Lilly highlighted lepodisiran and muvalaplin as the key drugs in…
-
BioAge’s NLRP3 inhibitor shows potential to reduce cardiovascular risk
BioAge’s NLRP3 inhibitor has shown potential to reduce high-sensitivity C-reactive protein (hsCRP), a key marker of cardiovascular risk, in an…
-
BMS and Johnson & Johnson terminate Phase III ACS trial due to likely failure
Editor’s note: This article has been updated to clarify that the collaboration was with Johnson & Johnson, not AstraZeneca as…
-
AHA 2025: satralizumab shows benefit in immune-driven pulmonary arterial hypertension
At the 2025 American Heart Association (AHA) Scientific Sessions in New Orleans, investigators from Japan presented results from the SATISFY-JP…
-
Long-term benefit of Amgen’s Repatha in reducing MACE shown in Phase III trial
Amgen's Repatha (evolocumab) has shown benefit in a long-term study in reducing cardiovascular incidents in patients without a prior history…
-
Podcast: key trials and trends from ESC Congress 2025
Eyes in the pharma and medtech industries are directed to the European Society of Cardiology (ESC) Congress every year to…
-
MSD’s oral PCSK9 scores Phase III hat-trick
MSD’s oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor has succeeded in a third Phase III trial in patients with…
